IFNB1 and myeloid sarcoma: The model that included autoimmune diagnosis had modest predictive power (R2 = 0.28) and identified the diagnosis of MS as a predictor of low anti–spike IgG response (Supplemental Figure 6A) except in patients treated with IFN-β or glatiramer acetate who mounted significantly higher anti–spike IgG values than the rest of the autoimmune cohort (P < 0.01), comparable with the HC (Supplemental Figure 6B).